adecatumumab
mAbexperimental
Adecatumumab (MT201) is a recombinant human IgG1 monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule, with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2009 (NCT00866944)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Epithelial cell adhesion moleculeINHIBITOR
EPCAM inhibitor
Moderate affinity for EpCAM.
- Epithelial cell adhesion moleculeImmunity, passive
EPCAM immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAdecatumumab ↗
- ChEMBLCHEMBL2108018 ↗
Also known as
- adecatumumab
- adecatumumab
- adecatumumab
- adecatumumab
- mt-201
- mt201 antibody, human
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00866944 | Phase 2 | Mar 1, 2009 | Amgen, Centre Paul Strauss |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 1 | 1 | 1 | 2009 |
| Centre Paul Strauss | Academic/Hospital | 1 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1